Gerald Commissiong - OS Therapies Chief Officer
| OSTX Stock | 5.16 0.05 0.98% |
Executive
Gerald Commissiong is Chief Officer of OS Therapies Incorporated
| Age | 42 |
| Address | 15825 Shady Grove Road, Rockville, MD, United States, 20850 |
| Phone | 410-297-7793 |
| Web | https://ostherapies.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stephen Wargacki | Aquestive Therapeutics | 46 | |
| Sebastien Martel | BRP Inc | 52 | |
| Minh Tran | BRP Inc | 40 | |
| Ernest Toth | Aquestive Therapeutics | 65 | |
| Kenneth Marshall | Aquestive Therapeutics | 65 | |
| Darlan Monterisi | Playtika Holding Corp | N/A | |
| MBA MD | Aquestive Therapeutics | 67 | |
| Mauro JD | Universal Display | 58 | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
| Gili Brudno | Playtika Holding Corp | 50 | |
| Mark Schallenberger | Xtant Medical Holdings | 38 | |
| Patrick Dussault | BRP Inc | N/A | |
| Chandran Nair | Universal Display | 55 | |
| Stephane Bilodeau | BRP Inc | 57 | |
| Michael Esq | Playtika Holding Corp | 53 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Carl MD | Aquestive Therapeutics | 54 | |
| Catherine Lundy | Xtant Medical Holdings | N/A | |
| Ofer Kinberg | Playtika Holding Corp | 44 | |
OS Therapies Leadership Team
Elected by the shareholders, the OS Therapies' board of directors comprises two types of representatives: OS Therapies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OSTX. The board's role is to monitor OS Therapies' management team and ensure that shareholders' interests are well served. OS Therapies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OS Therapies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Doll, Chief Staff | ||
| Robert Petit, Chief Officer | ||
| Christopher Acevedo, Chief Officer | ||
| Paul MPH, President Founder | ||
| Gerald Commissiong, Chief Officer |
OSTX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OS Therapies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 90.74 M | ||||
| Shares Outstanding | 20.88 M | ||||
| Shares Owned By Insiders | 24.83 % | ||||
| Number Of Shares Shorted | 8.93 K | ||||
| EBITDA | (3.18 M) | ||||
| Net Income | (7.79 M) | ||||
| Total Debt | 14.61 M | ||||
| Book Value Per Share | (4.52) X | ||||
| Cash Flow From Operations | (3.01 M) | ||||
| Short Ratio | 0.01 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OSTX Stock Analysis
When running OS Therapies' price analysis, check to measure OS Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OS Therapies is operating at the current time. Most of OS Therapies' value examination focuses on studying past and present price action to predict the probability of OS Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OS Therapies' price. Additionally, you may evaluate how the addition of OS Therapies to your portfolios can decrease your overall portfolio volatility.